Your institution may have access to this item. Find your institution then sign in to continue.
Title
Blinatumomab is associated with favorable outcomes in patients with B‐cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10<sup>−4</sup> and higher.